Table 1.
Characteristics of the included studies.
| Study | Year | Phase | Treatment arms | No. of patients | Median age (years) | Male (%) | Cancer type | Follow-up time (months) | NCT number |
|---|---|---|---|---|---|---|---|---|---|
| Paz-Ares et al. (10) | 2018 | 3 | Pembrolizumab+carboplatin+paclitaxel/nab-paclitaxel | 278 | 65 (29–87) | 220 (79.1) | Squamous non–small-cell lung cancer | 21 | 02775435 |
| Placebo+carboplatin+paclitaxel/nab-paclitaxel | 281 | 65 (36–88) | 235 (83.6) | ||||||
| Gandhi et al. (11) | 2018 | 3 | Pembrolizumab+pemetrexed+platinum | 410 | 65 (34–84) | 254 (62.0) | Metastatic non–small-cell lung cancer | 21 | 02578680 |
| Placebo+pemetrexed+platinum | 206 | 63.5 (34–84) | 109 (52.9) | ||||||
| Borghaei et al. (12) | 2018 | 2 | Pembrolizumab+pemetrexed+carboplatin | 60 | 62.5 (54–70) | 22 (37) | Advanced non-small cell lung cancer | 36 | 02039674 |
| Pemetrexed+carboplatin | 63 | 63.2 (58–70) | 26 (41) | ||||||
| Schmid et al. (13) | 2018 | 3 | Atezolizumab+nab-paclitaxed | 451 | 55 (20–82) | 3 (0.7) | Advanced triple-negative breast cancer | 36 | 02425891 |
| Placebo+nab-paclitaxel | 451 | 56 (26–86) | 1 (0.2) | ||||||
| Horn et al. (14) | 2018 | 3 | Atezolizumab+carboplatin+etoposide | 201 | 64 (28–60) | 129 (64.2) | Extensive-stage small-cell lung cancer | 24 | 02763579 |
| Placebo+carboplatin+etoposide | 202 | 64 (26–87) | 132 (65.3) | ||||||
| Lynch et al. (15) | 2012 | 2 | Ipilimumab+carboplatin+paclitaxel | 138 | 60 (36–88) | 102 (74) | Stage IIIB/IV non–small-cell lung cancer | 26 | 00527735 |
| Placebo+carboplatin+paclitaxel | 66 | 62 (36–82) | 49 (74) | ||||||
| Reck et al. (16) | 2012 | 2 | Ipilimumab+paclitaxel/carboplatin | 85 | 58 (43–80) | 65 (76) | Extensive-stage small-cell lung cancer | 24 | 00527735 |
| Placebo+paclitaxel/carboplatin | 45 | 58 (42–82) | 33 (73) | ||||||
| Reck et al. (17) | 2016 | 3 | Ipilimumab+platinum+etoposide | 478 | 62 (39–85) | 317 (66) | Extensive-stage small-cell lung cancer | 32 | 01450761 |
| Placebo+platinum+etoposide | 476 | 63 (36–81) | 326 (68) | ||||||
| Govindan et al. (18) | 2017 | 3 | Ipilimumab+paclitaxel+carboplatin | 388 | 64 (28–84) | 326 (84) | Advanced squamous non–small-cell lung cancer | 36 | 01285609 |
| Placebo+paclitaxel+carboplatin | 361 | 64 (28–85) | 309 (85) | ||||||
| Robert et al. (19) | 2011 | 3 | Ipilimumab+dacarbazine | 250 | 57.5 | 152 (60.8) | Metastatic melanoma | 48 | 00324155 |
| Placebo+dacarbazine | 252 | 56.4 | 149 (59.1) |